Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Dopaminergic Modulation on Brain Computer Interface Efficacy

NCT06729658 is registered in ClinicalTrials.gov with Max Planck Institute for Human Cognitive and Brain Sciences as lead sponsor.

NCT NCT06729658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06729658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Dopaminergic Modulation on Brain Computer Interface Efficacy
Lead sponsor
Max Planck Institute for Human Cognitive and Brain Sciences
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2017
Completion date
August 6, 2024
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants